

Supplementary Online Content

Guntupalli SR, Brennecke A, Behbakht K, et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. *JAMA Netw Open*. 2020;3(6):e207410. doi:10.1001/jamanetworkopen.2020.7410

eTable 1. Description of Major Bleeding and Venous Thromboembolic Events

eTable 2. Grade Level of Related and Anticipated Adverse Events

eFigure. Treatment Diagram

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Description of Major Bleeding and Venous Thromboembolic Events


Patients	Event	Post-Operative Day	Surgery type	Treatment Arm
Major Bleeding Event				
Patient 1		2	Robotic assisted hysterectomy, BSO	apixaban
Patient 2		4	Abdominal hysterectomy BSO, tumor debulking	enoxaparin
VTE Event				
Patient 1	PE	4	Tumor debulking, omentectomy	apixaban
Patient 2	DVT	32	Radical hysterectomy, BSO, tumor debulking	enoxaparin
Patient 3	DVT, PE	69	Radical vulvectomy, bilateral groin dissection	apixaban
Patient 4	DVT	65	Abdominal hysterectomy BSO, tumor debulking	enoxaparin
Patient 5	DVT	52	Laparotomy loop colostomy	enoxaparin

eTable 2. Grade Level of Related and Anticipated Adverse Events

Adverse Event	Any (n=400)	Grade 3	Grade 4	Grade 5
Clinically relevant non-major bleeding events				
Hematoma	5 (<1.0)	1 (<1.0)	0	0
Bruising	15 (3.8)	0	0	0
Epistaxis	5 (<1.0)	0	0	0
Vaginal spotting/discharge/bleeding	4 (<1.0)	1 (<1.0)	0	0
Wound infection	6 (1.5)	11 (2.8)	0	0
Dizziness	11 (2.8)	0	0	0
Suspected allergic reaction	2 (<1.0)	0	0	0
Arthralgia	9 (2.3)	0	0	0
Skin rash/cellulitis	3 (<1.0)	0	0	0
Abscess/discharge from incision	0	2 (<1.0)	0	0
Headache	12 (3.0)	0	0	0

Values reported are n (%)

eFigure. Treatment Diagram



Flow diagram of protocol treatment plan.